First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

Background Infliximab (IFX) is one of the treatments of choice for corticosteroid-refractory and corticosteroid-dependent ulcerative colitis (UC). A high serum trough level of IFX (TL) is reported to be associated with sustained efficacy during maintenance treatment. As part of a phase 3 randomized...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2016-03, Vol.51 (3), p.241-251
Main Authors: Kobayashi, Taku, Suzuki, Yasuo, Motoya, Satoshi, Hirai, Fumihito, Ogata, Haruhiko, Ito, Hiroaki, Sato, Noriko, Ozaki, Kunihiko, Watanabe, Mamoru, Hibi, Toshifumi
Format: Article
Language:English
Subjects:
Abdominal Surgery
Adult
Analysis
Clinical trials
Colitis, Ulcerative - blood
Colitis, Ulcerative - drug therapy
Colorectal Surgery
Corticosteroids
Double-Blind Method
Drug Administration Schedule
Enzyme-linked immunosorbent assay
Female
Gastroenterology
Gastrointestinal Agents - administration & dosage
Gastrointestinal Agents - adverse effects
Gastrointestinal Agents - blood
Gastrointestinal Agents - therapeutic use
Hepatology
Humans
Infliximab - administration & dosage
Infliximab - adverse effects
Infliximab - blood
Infliximab - therapeutic use
Male
Medical colleges
Medicine
Medicine & Public Health
Middle Aged
Original Article—Alimentary Tract
Original —Alimentary Tract
Prognosis
Prospective Studies
Surgical Oncology
Treatment Outcome
Ulcerative colitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!